Blair, J. M., Webber, M. A., Baylay, A. J., Ogbolu, D. O. & Piddock, L. J. Molecular mechanisms of antibiotic resistance. Nat. Rev. Microbiol.13, 42–51 (2015). CASPubMed Google Scholar
Bigger, J. W. The bactericidal action of penicillin on Staphylococcus pyogenes. Irish J. Med. Sci.19, 585–595 (1944). Google Scholar
Cohen, N. R., Lobritz, M. A. & Collins, J. J. Microbial persistence and the road to drug resistance. Cell Host Microbe13, 632–642 (2013). CASPubMedPubMed Central Google Scholar
Lewis, K. Persister cells, dormancy and infectious disease. Nat. Rev. Microbiol.5, 48–56 (2007). CASPubMed Google Scholar
Fisher, R. A., Gollan, B. & Helaine, S. Persistent bacterial infections and persister cells. Nat. Rev. Microbiol.15, 453–464 (2017). This review summarizes knowledge of persister cells in bacteria. CASPubMed Google Scholar
Michiels, J. E., Van den Bergh, B., Verstraeten, N. & Michiels, J. Molecular mechanisms and clinical implications of bacterial persistence. Drug Resist. Updat.29, 76–89 (2016). PubMed Google Scholar
Van den Bergh, B., Fauvart, M. & Michiels, J. Formation, physiology, ecology, evolution and clinical importance of bacterial persisters. FEMS Microbiol. Rev.41, 219–251 (2017). PubMed Google Scholar
Srinivas, V., Arrieta-Ortiz, M., Peterson, E. L. R. & Baliga, N. S. Characterization and elimination of stochastically generated persister subpopulation in mycobacteria. Preprint at bioRxivhttps://www.biorxiv.org/content/10.1101/463232v1 (2018).
Delarze, E. & Sanglard, D. Defining the frontiers between antifungal resistance, tolerance and the concept of persistence. Drug Resist. Updat.23, 12–19 (2015). PubMed Google Scholar
Vera-Ramirez, L. & Hunter, K. W. Tumor cell dormancy as an adaptive cell stress response mechanism. F1000Res.6, 2134 (2017). PubMedPubMed Central Google Scholar
Fairlamb, A. H., Gow, N. A., Matthews, K. R. & Waters, A. P. Drug resistance in eukaryotic microorganisms. Nat. Microbiol.1, 16092 (2016). CASPubMedPubMed Central Google Scholar
Kaye, P. & Scott, P. Leishmaniasis: complexity at the host-pathogen interface. Nat. Rev. Microbiol.9, 604–615 (2011). CASPubMed Google Scholar
Yam, X. Y. & Preiser, P. R. Host immune evasion strategies of malaria blood stage parasite. Mol. Biosyst.13, 2498–2508 (2017). CASPubMed Google Scholar
Cabral, D. J., Wurster, J. I. & Belenky, P. Antibiotic persistence as a metabolic adaptation: stress, metabolism, the host, and new directions. Pharmaceuticals11, E14 (2018). PubMed Google Scholar
Harms, A., Brodersen, D. E., Mitarai, N. & Gerdes, K. Toxins, targets, and triggers: an overview of toxin-antitoxin biology. Mol. Cell.70, 768–784 (2018). CASPubMed Google Scholar
Sanchez-Valdez, F. J., Padilla, A., Wang, W., Orr, D. & Tarleton, R. L. Spontaneous dormancy protects Trypanosoma cruzi during extended drug exposure. eLife7, e34039 (2018). This is the first unequivocal demonstration of drug-resistant persister subpopulations in kinetoplastid parasites. PubMedPubMed Central Google Scholar
Mandell, M. A. & Beverley, S. M. Continual renewal and replication of persistent Leishmania major parasites in concomitantly immune hosts. Proc. Natl Acad. Sci. USA114, E801–E810 (2017). This work reports the discovery of mixed populations of replicating and non-replicating subpopulations ofL. majorin persistent infections in mice. CASPubMed Google Scholar
Ashley, E. A., Pyae Phyo, A. & Woodrow, C. J. Malaria. Lancet391, 1608–1621 (2018). PubMed Google Scholar
Holmes, M. J., Augusto, L. D. S., Zhang, M., Wek, R. C. & Sullivan, W. J. Jr. Translational control in the latency of apicomplexan parasites. Trends Parasitol.33, 947–960 (2007). Google Scholar
Imwong, M. Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J. Infect. Dis.195, 927–933 (2007). CASPubMed Google Scholar
Shanks, G. D. & White, N. J. The activation of vivax malaria hypnozoites by infectious diseases. Lancet Infect. Dis.13, 900–906 (2013). PubMed Google Scholar
Krotoski, W. A. et al. Observations on early and late post-sporozoite tissue stages in primate malaria. I. Discovery of a new latent form of Plasmodium cynomolgi (the hypnozoite), and failure to detect hepatic forms within the first 24 hours after infection. Am. J. Trop. Med. Hyg.31, 24–35 (1982). CASPubMed Google Scholar
Krotoski, W. A. et al. Observations on early and late post-sporozoite tissue stages in primate malaria. IV. Pre-erythrocytic schizonts and/or hypnozoites of Chesson and North Korean strains of Plasmodium vivax in the chimpanzee. Am. J. Trop. Med. Hyg.35, 263–274 (1986). CASPubMed Google Scholar
Dembele, L. et al. Persistence and activation of malaria hypnozoites in long-term primary hepatocyte cultures. Nat. Med.20, 307–312 (2014). This work introduces a model forP. cynomolgihypnozoite characterization in cultured hepatocytes. CASPubMed Google Scholar
Gural, N. et al. In vitro culture, drug sensitivity, and transcriptome of Plasmodium vivax hypnozoites. Cell Host Microbe23, 395–406 (2018). This work introduces a model forP. vivaxhypnozoite characterization in cultured hepatocytes. CASPubMed Google Scholar
Roth, A. et al. A comprehensive model for assessment of liver stage therapies targeting Plasmodium vivax and Plasmodium falciparum. Nat. Commun.9, 1837 (2018). This work reports an in vitro hepatocyte system to allow screening for drugs againstP. vivaxhypnozoite and replicative liver stages andP. falciparumliver stages. PubMedPubMed Central Google Scholar
Voorberg-van der Wel, A. et al. A comparative transcriptomic analysis of replicating and dormant liver stages of the relapsing malaria parasite Plasmodium cynomolgi. eLife6, e29605 (2017). PubMedPubMed Central Google Scholar
Bertschi, N. L. et al. Transcriptomic analysis reveals reduced transcriptional activity in the malaria parasite Plasmodium cynomolgi during progression into dormancy. eLife7, e41081 (2018). In this work, transcriptomic analysis demonstrates progressive changes in metabolism as hypnozoite form. PubMedPubMed Central Google Scholar
Voorberg-van der Wel, A. et al. Transgenic fluorescent Plasmodium cynomolgi liver stages enable live imaging and purification of Malaria hypnozoite-forms. PLOS ONE8, e54888 (2013). CASPubMedPubMed Central Google Scholar
Maher, S. P. et al. Microphysical space of a liver sinusoid device enables simplified long-term maintenance of chimeric mouse-expanded human hepatocytes. Biomed. Microdevices16, 727–736 (2014). PubMedPubMed Central Google Scholar
Mikolajczak, S. A. Plasmodium vivax liver stage development and hypnozoite persistence in human liver-chimeric mice. Cell Host Microbe17, 526–535 (2015). CASPubMedPubMed Central Google Scholar
Shaefer, C. et al. A recombinant antibody against Plasmodium vivax UIS4 for distinguishing replicating from dormant liver stages. Malar. J.17, 370 (2018). Google Scholar
Dow, G. S. et al. Radical curative efficacy of tafenoquine combination regimens in _Plasmodium cynomolgi_-infected Rhesus monkeys (Macaca mulatta). Malar. J.10, 212 (2011). CASPubMedPubMed Central Google Scholar
Alving, A. S. et al. Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine. J. Lab. Clin. Med.46, 301–306 (1955). CASPubMed Google Scholar
Bennett, J. W. et al. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N. Engl. J. Med.369, 1381–1382 (2013). CASPubMed Google Scholar
Pybus, B. S. et al. The metabolism of primaquine to its active metabolite is dependent on CYP 2D6. Malar. J.12, 212 (2013). CASPubMedPubMed Central Google Scholar
Milner, E. E. et al. Cytochrome P450 2D-mediated metabolism is not necessary for tafenoquine and primaquine to eradicate the erythrocytic stages of Plasmodium berghei. Malar. J.15, 588 (2016). PubMedPubMed Central Google Scholar
Vuong, C. et al. Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics. Antimicrob. Agents Chemother.59, 3864–3869 (2015). CASPubMedPubMed Central Google Scholar
Marcsisin, S. R. et al. Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: implications for the 8-aminoquinoline class of anti-malarial compounds. Malar. J.13, 2 (2014). PubMedPubMed Central Google Scholar
Baird, J. K., Battle, K. E. & Howes, R. E. Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms. Malar. J.17, 42 (2018). PubMedPubMed Central Google Scholar
Zeeman, A. M. et al. PI4 kinase is a prophylactic but not radical curative target in _Plasmodium vivax_-type malaria parasites. Antimicrob. Agents Chemother.60, 2858–2863 (2016). CASPubMedPubMed Central Google Scholar
Teuscher, F., Chen, N., Kyle, D. E., Gatton, M. L. & Cheng, Q. Phenotypic changes in artemisinin-resistant Plasmodium falciparum lines in vitro: evidence for decreased sensitivity to dormancy and growth inhibition. Antimicrob. Agents Chemother.56, 428–431 (2012). CASPubMedPubMed Central Google Scholar
Tucker, M. S., Mutka, T., Sparks, K., Patel, J. & Kyle, D. E. Phenotypic and genotypic analysis of in vitro-selected artemisinin-resistant progeny of Plasmodium falciparum. Antimicrob. Agents Chemother.56, 302–314 (2012). CASPubMedPubMed Central Google Scholar
Hott, A., Tucker, M. S., Casandra, D., Sparks, K. & Kyle, D. E. Fitness of artemisinin-resistant Plasmodium falciparum in vitro. J. Antimicrob. Chemother.70, 2787–2796 (2015). CASPubMedPubMed Central Google Scholar
Chen, N. et al. Fatty acid synthesis and pyruvate metabolism pathways remain active in dihydroartemisinin-induced dormant ring stages of Plasmodium falciparum. Antimicrob. Agents Chemother.58, 4773–4781 (2014). PubMedPubMed Central Google Scholar
Peatey, C. L. et al. A small subset of artemisinin induced dormant P. falciparum parasites maintain mitochondrial membrane potential and resume growth in vitro. J. Infect. Dis.212, 426–434 (2015). CASPubMed Google Scholar
Nakazawa, S., Kanbara, H. & Aikawa, M. Plasmodium falciparum: recrudescence of parasites in culture. Exp. Parasitol.81, 556–563 (1995). CASPubMed Google Scholar
Nakazawa, S., Maoka, T., Uemura, H., Ito, Y. & Kanbara, H. Malaria parasites giving rise to recrudescence in vitro. Antimicrob. Agents Chemother.46, 958–965 (2002). CASPubMedPubMed Central Google Scholar
Babbitt, S. E. et al. Plasmodium falciparum responds to amino acid starvation by entering into a hibernatory state. Proc. Natl Acad. Sci. USA109, E3278–E3287 (2012). CASPubMed Google Scholar
Painter, H. J. Mitochondrial electron transport inhibition and viability of intraerythrocytic Plasmodium falciparum. Antimicrob. Agents Chemother.54, 5281–5287 (2010). CASPubMedPubMed Central Google Scholar
van Biljon, R. et al. Inducing controlled cell cycle arrest and re-entry during asexual proliferation of Plasmodium falciparum malaria parasites. Sci. Rep.8, 16581 (2018). PubMedPubMed Central Google Scholar
Ismail, H. M. et al. Artemisinin activity-based probes identify multiple molecular targets within the asexual stage of the malaria parasites Plasmodium falciparum 3D7. Proc. Natl Acad. Sci. USA113, 2080–2085 (2016). CASPubMed Google Scholar
Wang, J. et al. Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum. Nat. Commun.6, 10111 (2018). Google Scholar
Bridgford, J. L. et al. Artemisinin kills malaria parasites by damaging proteins and inhibiting the proteasome. Nat. Commun.9, 3801 (2018). PubMedPubMed Central Google Scholar
Noedl, H. et al. Evidence of artemisinin-resistant malaria in western Cambodia. N. Engl. J. Med.359, 2619–2620 (2008). CASPubMed Google Scholar
Dondorp, A. M. et al. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med.361, 455–467 (2009). CASPubMedPubMed Central Google Scholar
Witkowski, B. et al. Increased tolerance to artemisinin in Plasmodium falciparum is mediated by a quiescence mechanism. Antimicrob. Agents Chemother.54, 1872–1877 (2010). In this study, after 3 years of selection in vitro, artemisinin-refractoryP. falciparumis isolated and refractoriness is linked to ring-stage growth arrest. CASPubMedPubMed Central Google Scholar
Ariey, F. et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature505, 50–55 (2014). This work reports the discovery of the link betweenPfk13mutations and artemisinin treatment failure in the field, which was shown to be related to ring-stage growth arrest. PubMed Google Scholar
Witkowski, B. et al. Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies. Lancet Infect. Dis.13, 1043–1049 (2013). CASPubMedPubMed Central Google Scholar
Straimer, J. et al. Drug resistance. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Science347, 428–431 (2015). CASPubMed Google Scholar
Tilley, L., Straimer, J., Gnädig, N. F., Ralph, S. A. & Fidock, D. A. Artemisinin action and resistance in Plasmodium falciparum. Trends Parasitol.32, 682–696 (2016). CASPubMedPubMed Central Google Scholar
Mbengue, A. A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria. Nature520, 683–687 (2015). CASPubMedPubMed Central Google Scholar
Heller, L. E. & Roepe, P. D. Quantification of free ferriprotoporphyrin IX heme and hemozoin for artemisinin sensitive versus delayed clearance phenotype Plasmodium falciparum malarial parasites. Biochemistry57, 6927–6934 (2018). CASPubMed Google Scholar
Demas, A. R. et al. Mutations in Plasmodium falciparum actin-binding protein coronin confer reduced artemisinin susceptibility. Proc. Natl Acad. Sci. USA115, 12799–12804 (2018). CASPubMed Google Scholar
Paloque, L., Ramadani, A. P., Mercereau-Puijalon, O., Augereau, J. M. & Benoit-Vical, F. Plasmodium falciparum: multifaceted resistance to artemisinins. Malar. J.15, 149 (2016). PubMedPubMed Central Google Scholar
Teuscher, F. et al. Artemisinin-induced dormancy in Plasmodium falciparum: duration, recovery rates, and implications in treatment failure. J. Infect. Dis.202, 1362–1368 (2010). PubMedPubMed Central Google Scholar
Dembele, L. et al. The Plasmodium PI(4)K inhibitor KDU691 selectively inhibits dihydroartemisinin-pretreated Plasmodium falciparum ring-stage parasites. Sci. Rep.7, 2325 (2017). CASPubMedPubMed Central Google Scholar
Dembele, L. et al. Imidazolopiperazines kill both rings and dormant rings in wild-type and K13 artemisinin-resistant Plasmodium falciparum in vitro. Antimicrob. Agents Chemother.62, e02235-17 (2018). CASPubMedPubMed Central Google Scholar
O’Neill, P. M. et al. A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance. Nat. Commun.24, 15159 (2017). Google Scholar
Duvalsaint, M. & Kyle, D. E. Phytohormones, isoprenoids, and role of the apicoplast in recovery from dihydroartemisinin-induced dormancy of Plasmodium falciparum. Antimicrob. Agents Chemother.62, e01771-17 (2018). PubMedPubMed Central Google Scholar
Zhang, M. et al. Inhibiting the Plasmodium eIF2alpha kinase PK4 prevents artemisinin-Induced latency. Cell Host Microbe.22, 766–776 (2017). CASPubMedPubMed Central Google Scholar
Zhang, M. et al. The Plasmodium eukaryotic initiation factor-2alpha kinase IK2 controls the latency of sporozoites in the mosquito salivary glands. J. Exp. Med.207, 1465–1474 (2010). CASPubMedPubMed Central Google Scholar
Dubey, J. P. Foodborne and waterborne zoonotic sarcocystosis. Food Water. Parasitol.1, 2–11 (2015). Google Scholar
Seeber, F. & Steinfelder, S. Recent advances in understanding apicomplexan parasites. F1000Res.5, 1369 (2016). Google Scholar
Dubey, J. P. Toxoplasmosis of Animals and Humans (CRC Press, 2010).
Watts, E. et al. Novel approaches reveal that Toxoplasma gondii bradyzoites within tissue cysts are dynamic and replicating entities in vivo. mBio6, e01155-15 (2015). This work demonstrates that bradyzoites are not dormant but rather that they replicate slowly and asynchronously within the tissue cyst. CASPubMedPubMed Central Google Scholar
Hunter, C. A. & Sibley, L. D. Modulation of innate immunity by Toxoplasma gondii virulence effectors. Nat. Rev. Microbiol.10, 766–778 (2012). CASPubMedPubMed Central Google Scholar
Dubey, J. P. Bradyzoite-induced murine toxoplasmosis: stage conversion pathogenesis, and tissue cyst formation in mice fed bradyzoites of different strains of Toxoplasma gondii. J. Eukaryot. Microbiol.44, 592–602 (1997). CASPubMed Google Scholar
Israelski, D. M. & Remington, J. S. Toxoplasmosis in the non-AIDS immunocompromised host. Curr. Clin. Top. Infect. Dis.13, 322–356 (1993). CASPubMed Google Scholar
Mariuz, P. & Steigbigel, R. T. in Toxoplasmosis: A Comprehensive Clinical Guide (eds Joynson, D. H. M. & Wreghitt, T. G.) 147–177 (Cambridge Univ. Press, 2007).
Dunay, I. R., Gajurel, K., Dhakal, R., Liesenfeld, O. & Montoya, J. G. Treatment of Toxoplasmosis: historical perspective, animal models, and current clinical practice. Clin. Microbiol. Rev.31, e00057-17 (2018). This work provides a current summary of treatment options and limitations for toxoplasmosis. PubMed Google Scholar
Behnke, M. S., Zhang, T. P., Dubey, J. P. & Sibley, L. D. Toxoplasma gondii merozoite gene expression analysis with comparison to the life cycle discloses a unique expression state during enteric development. BMC Genomics15, 350 (2014). PubMedPubMed Central Google Scholar
Radke, J. R. et al. Changes in the expression of human cell division autoantigen-1 influence Toxoplasma gondii growth and development. PLOS Pathog.2, e105 (2006). PubMedPubMed Central Google Scholar
Behnke, M., Radke, J., Smith, A. T., Sullivan, W. J. & White, M. W. The transcription of bradyzoite genes in Toxoplasma gondii is controlled by autonomous promoter elements. Mol. Microbiol.68, 1502–1518 (2009). Google Scholar
Behnke, M. S. et al. Coordinated progression through two subtranscriptomes underlies the tachyzoite cycle of Toxoplasma gondii. PLOS ONE5, e12354 (2010). PubMedPubMed Central Google Scholar
Hong, D. P., Radke, J. B. & White, M. W. Opposing transcriptional mechanisms regulate Toxoplasma development. mSphere2, e00347-16 (2017). CASPubMedPubMed Central Google Scholar
Huang, S. et al. Toxoplasma gondii AP2IX-4 regulates gene expression during bradyzoite development. mSphere2, e00054-17 (2017). PubMedPubMed Central Google Scholar
Radke, J. B. et al. ApiAP2 transcription factor restricts development of the Toxoplasma tissue cyst. Proc. Natl Acad. Sci. USA110, 6871–6876 (2013). CASPubMed Google Scholar
Radke, J. B. et al. Transcriptional repression by ApiAP2 factors is central to chronic toxoplasmosis. PLOS Pathog.14, e1007035 (2018). PubMedPubMed Central Google Scholar
Walker, R. et al. The Toxoplasma nuclear factor TgAP2XI-4 controls bradyzoite gene expression and cyst formation. Mol. Microbiol.87, 641–655 (2013). CASPubMed Google Scholar
Painter, H. J., Campbell, T. L. & Llinas, M. The Apicomplexan AP2 family: integral factors regulating Plasmodium development. Mol. Biochem. Parasitol.176, 1–7 (2011). CASPubMed Google Scholar
Sinha, A. et al. A cascade of DNA-binding proteins for sexual commitment and development in Plasmodium. Nature507, 253–257 (2014). CASPubMedPubMed Central Google Scholar
Yuda, M., Iwanaga, S., Shigenobu, S., Kato, T. & Kaneko, I. Transcription factor AP2-Sp and its target genes in malarial sporozoites. Mol. Microbiol.75, 854–863 (2010). CASPubMed Google Scholar
White, M. W., Radke, J. R. & Radke, J. B. Toxoplasma development — turn the switch on or off? Cell. Microbiol.16, 466–472 (2014). This work summarizes how host and parasite-specific factors control stage differentiation ofT. gondii. CASPubMed Google Scholar
Fox, B. A., Gigley, J. P. & Bzik, D. J. Toxoplasma gondii lacks the enzymes required for de novo arginine biosynthesis and arginine starvation triggers cyst formation. Int. J. Parasitol.34, 323–331 (2004). CASPubMed Google Scholar
Soête, M., Camus, D. & Dubremetz, J. F. Experimental induction of bradyzoite-specific antigen expression and cyst formation by the RH strain of Toxoplasma gondii in vitro. Exp. Parasitol.78, 361–370 (1994). PubMed Google Scholar
Bohne, W., Heesemann, J. & Gross, U. Reduced replication of Toxoplasma gondii is necessary for induction of bradyzoite-specific antigens: a possible role for nitric oxide in triggering stage conversion. Infect. Immun.62, 1761–1767 (1994). CASPubMedPubMed Central Google Scholar
Ferreira-da-Silva Mda, F., Takács, A. C., Barbosa, H. S., Gross, U. & Lüder, C. G. Primary skeletal muscle cells trigger spontaneous Toxoplasma gondii tachyzoite-to-bradyzoite conversion at higher rates than fibroblasts. Int. J. Med. Microbiol.229, 381–388 (2009). Google Scholar
Tanaka, N., Ashour, D., Dratz, E. & Halonen, S. Use of human induced pluripotent stem cell-derived neurons as a model for cerebral toxoplasmosis. Microbes Infect.18, 496–504 (2016). CASPubMed Google Scholar
Blader, I. J. & Saeij, J. P. Communication between Toxoplasma gondii and its host: impact on parasite growth, development, immune evasion, and virulence. APMIS117, 458–476 (2009). CASPubMedPubMed Central Google Scholar
Jeffers, V., Tampaki, Z., Kim, K. & Sullivan, W. J. Jr. A latent ability to persist: differentiation in Toxoplasma gondii. Cell. Mol. Life Sci.75, 2355–2373 (2018). CASPubMedPubMed Central Google Scholar
Su, C. et al. Recent expansion of Toxoplasma through enhanced oral transmission. Science299, 414–416 (2003). CASPubMed Google Scholar
Dubey, J. P., Miller, N. L. & Frenkel, J. K. The Toxoplasma gondii oocyst from cat feces. J. Exp. Med.132, 636–662 (1970). CASPubMedPubMed Central Google Scholar
Jones, J. L. & Dubey, J. P. Foodborne toxoplasmosis. Clin. Infect. Dis.55, 864–851 (2012). Google Scholar
Torgerson, P. R. & Mastroiacovo, P. The global burden of congenital toxoplasmosis: a systematic review. Bull. World Health Organ.91, 501–508 (2013). PubMedPubMed Central Google Scholar
Pfaff, A. W. et al. New clinical and experimental insights into old world and neotropical ocular toxoplasmosis. Int. J. Parasitol.44, 99–107 (2013). PubMed Google Scholar
Rutaganira, F. U. et al. Inhibition of calcium dependent protein kinase 1 (CDPK1) by pyrazolopyrimidine analogs decreases establishment and reoccurrence of central nervous system disease by Toxoplasma gondii. J. Med. Chem.60, 9976–9989 (2017). CASPubMedPubMed Central Google Scholar
Chen, M., Osman, I. & Orlow, S. J. Antifolate activity of pyrimethamine enhances temozolomide-induced cytotoxicity in melanoma cells. Mol. Cancer Res.7, 703–712 (2009). CASPubMed Google Scholar
Tomita, T. et al. The Toxoplasma gondii cyst wall protein CST1 is critical for cyst wall integrity and promotes bradyzoite persistence. PLOS Pathog.9, e1003823 (2013). PubMedPubMed Central Google Scholar
Lemgruber, L., Lupetti, P., Martins-Duarte, E. S., De Souza, W. & Vommaro, R. C. The organization of the wall filaments and characterization of the matrix structures of Toxoplasma gondii cyst form. Cell. Microbiol.13, 1920–1932 (2011). CASPubMed Google Scholar
Spalenka, J. et al. Discovery of new inhibitors of Toxoplasma gondii via the pathogen box. Antimicrob. Agents Chemother.62, e01640-17 (2018). PubMedPubMed Central Google Scholar
Adeyemi, O. S., Sugi, T., Han, Y. & Kato, K. Screening of chemical compound libraries identified new anti-Toxoplasma gondii agents. Parasitol. Res.117, 355–363 (2018). PubMed Google Scholar
Benmerzouga, I. et al. Guanabenz repurposed as an antiparasitic with activity against acute and latent toxoplasmosis. Antimicrob. Agents Chemother.59, 6939–6945 (2015). CASPubMedPubMed Central Google Scholar
Dittmar, A. J., Drozda, A. A. & Blader, I. J. Drug repurposing screening identifies novel compounds that effectively inhibit Toxoplasma gondii growth. mSphere1, e00042-15 (2016). CASPubMedPubMed Central Google Scholar
Konrad, C., Queener, S. F., Wek, R. C. & Sullivan, W. J. Jr. Inhibitors of eIF2alpha dephosphorylation slow replication and stabilize latency in Toxoplasma gondii. Antimicrob. Agents Chemother.57, 1815–1822 (2013). CASPubMedPubMed Central Google Scholar
Radke, J. B., Burrows, J. N., Goldberg, D. E. & Sibley, L. D. Evaluation of current and emerging antimalarial medicines for inhibition of Toxoplasma gondii growth in vitro. ACS Infect. Dis.4, 1264–1274 (2018). This work evaluates the sensitivity ofT. gondiito current drugs and advanced leads for malaria treatment. CAS Google Scholar
McFadden, D. C., Tomavo, S., Berry, E. A. & Boothroyd, J. C. Characterization of cytochrome b from Toxoplasma gondii and Qo domain mutations as a mechanism of atovaquone-resistance. Mol. Biochem. Parasitol.108, 1–12 (2000). CASPubMed Google Scholar
Alday, P. H. et al. Genetic evidence for cytochrome b Qi site inhibition by 4(1H)-quinolone-3-diarylethers and antimycin in Toxoplasma gondii. Antimicrob. Agents Chemother.61, e01866-16 (2017). CASPubMedPubMed Central Google Scholar
Tekwani, B. L. & Walker, L. A. 8-Aminoquinolines: future role as antiprotozoal drugs. Curr. Opin. Infect. Dis.19, 623–631 (2006). CASPubMed Google Scholar
Pérez-Molina, J. A. & Molina, I. Chagas disease. Lancet391, 82–94 (2017). PubMed Google Scholar
Dumoulin, P. C. & Burleigh, B. A. Stress-induced proliferation and cell cycle plasticity of intracellular Trypanosoma cruzi Amastigotes. mBio9, e00673-18 (2018). CASPubMedPubMed Central Google Scholar
Francisco, A. F. et al. Biological factors that impinge on Chagas disease drug development. Parasitology144, 1871–1880 (2017). PubMedPubMed Central Google Scholar
Lewis, M. D. et al. Bioluminescence imaging of chronic Trypanosoma cruzi infections reveals tissue-specific parasite dynamics and heart disease in the absence of locally persistent infection. Cell. Microbiol.16, 1285–1300 (2014). CASPubMedPubMed Central Google Scholar
Sosa Estani, S. et al. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas’ disease. Am. J. Trop. Med. Hyg.59, 526–529 (1998). CASPubMed Google Scholar
Viotti, R. et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann. Intern. Med.144, 724–734 (2006). This work demonstrates in long-term follow-up studies the clinical benefits of treatment of chronicT. cruziinfection in humans. CASPubMed Google Scholar
Bern, C. A new epoch in antitrypanosomal treatment for Chagas disease. J. Am. Coll. Cardiol.69, 948–950 (2017). PubMed Google Scholar
Weatherly, D. B., Peng, D. & Tarleton, R. L. Recombination-driven generation of the largest pathogen repository of antigen variants in the protozoan Trypanosoma cruzi. BMC Genomics17, 729 (2016). PubMedPubMed Central Google Scholar
Bustamante, J. M. et al. New, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice. J. Infect. Dis.209, 150–162 (2014). CASPubMed Google Scholar
Alvarez, M. G. et al. Seronegative conversion after incomplete benznidazole treatment in chronic Chagas disease. Trans. R. Soc. Trop. Med. Hyg.106, 636–638 (2012). CASPubMed Google Scholar
MacLean, L. M. et al. Development of Trypanosoma cruzi in vitro assays to identify compounds suitable for progression in Chagas’ disease drug discovery. PLOS Negl. Trop. Dis.12, e0006612 (2018). PubMedPubMed Central Google Scholar
Alvarez, M. G. et al. New scheme of intermittent benznidazole administration in patients chronically infected with Trypanosoma cruzi: a pilot short-term follow-up study with adult patients. Antimicrob. Agents Chemother.60, 833–837 (2016). CASPubMedPubMed Central Google Scholar
Wilkinson, S. R., Taylor, M. C., Horn, D., Kelly, J. M. & Cheeseman, I. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc. Natl Acad. Sci. USA105, 5022–5027 (2008). CASPubMed Google Scholar
Burza, S., Croft, S. L. & Boelaert, M. Leishmaniasis. Lancet392, 951–970 (2018). PubMed Google Scholar
Sundar, S. & Chakravarty, J. Leishmaniasis: an update of current pharmacotherapy. Expert Opin. Pharmacother.14, 53–63 (2013). CASPubMed Google Scholar
Mukhopadhyay, D., Dalton, J. E., Kaye, P. M. & Chatterjee, M. Post kala-azar dermal leishmaniasis: an unresolved mystery. Trends Parasitol.30, 65–74 (2014). PubMedPubMed Central Google Scholar
Marovich, M. A. et al. Leishmaniasis recidivans recurrence after 43 years: a clinical and immunologic report after successful treatment. Clin. Infect. Dis.33, 1076–1079 (2001). CASPubMed Google Scholar
Ponte-Sucre, A. et al. Drug resistance and treatment failure in leishmaniasis: a 21st century challenge. PLOS Negl. Trop. Dis.11, e0006052 (2017). PubMedPubMed Central Google Scholar
Imamura, H. et al. Evolutionary genomics of epidemic visceral leishmaniasis in the Indian subcontinent. eLife5, e12613 (2016). PubMedPubMed Central Google Scholar
Carnielli, J. B. T. et al. A Leishmania infantum genetic marker associated with miltefosine treatment failure for visceral leishmaniasis. EBioMedicine36, 83–91 (2018). PubMedPubMed Central Google Scholar
Pountain, A. W. et al. Genomic instability at the locus of sterol C24-methyltransferase promotes amphotericin B resistance in Leishmania parasites. PLOS Negl Trop. Dis.13, e0007052 (2019). PubMedPubMed Central Google Scholar
Purkait, B. et al. Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani. Antimicrob. Agents Chemother.56, 1031–1041 (2012). CASPubMedPubMed Central Google Scholar
Kloehn, J., Saunders, E. C., O’Callaghan, S., Dagley, M. J. & McConville, M. J. Characterization of metabolically quiescent Leishmania parasites in murine lesions using heavy water labeling. PLOS Pathog.11, e1004683 (2015). This work uses heavy water labelling incorporation into parasite biopolymers in vivo and reveals very slow net replication rates ofL. mexicanapopulations in mice. CASPubMedPubMed Central Google Scholar
Saunders, E. C. et al. Induction of a stringent metabolic response in intracellular stages of Leishmania mexicana leads to increased dependence on mitochondrial metabolism. PLOS Pathog.10, e1003888 (2014). PubMedPubMed Central Google Scholar
Jara, M. et al. Macromolecular biosynthetic parameters and metabolic profile in different life stages of Leishmania braziliensis: Amastigotes as a functionally less active stage. PLOS ONE12, e0180532 (2017). PubMedPubMed Central Google Scholar
Tegazzini, D. et al. Replicative in vitro assay for drug discovery against Leishmania donovani. Antimicrob. Agents Chemother.60, 3524–3532 (2016). CASPubMedPubMed Central Google Scholar
Wasunna, M. et al. Efficacy and safety of AmBisome in combination with sodium stibogluconate or miltefosine and miltefosine monotherapy for African visceral leishmaniasis: phase II randomized trial. PLOS Negl Trop. Dis.14, e0004880 (2016). Google Scholar
Carter, N. S. et al. Adaptive responses to purine starvation in Leishmania donovani. Mol. Microbiol.78, 92–107 (2010). CASPubMedPubMed Central Google Scholar
Martin, J. L. et al. Metabolic reprogramming during purine stress in the protozoan pathogen Leishmania donovani. PLOS Pathog.10, e1003938 (2014). This work uses a proteomics and transcriptomics approach to probe changes inL. donovaninon-proliferative promastigotes selected in purine-free medium. PubMedPubMed Central Google Scholar
Jara, M. et al. Tracking of quiescence in Leishmania by quantifying the expression of GFP in the ribosomal DNA locus. Preprint at bioRxivhttps://www.biorxiv.org/content/10.1101/641290v1 (2019). This work reports the use of fluorescent dyes and GFP expression from the ribosomal locus, revealing mixed dividing versus non-dividing amastigote populations ofL. mexicanaandL. braziliensisin vitro and in vivo.
Fox, B. A., Belperron, A. A. & Bzik, D. J. Negative selection of herpes simplex virus thymidine kinase in Toxoplasma gondii. Mol. Biochem. Parasitol.116, 85–88 (2001). CASPubMed Google Scholar
Merrick, C. J. Transfection with thymidine kinase permits bromodeoxyuridine labelling of DNA replication in the human malaria parasite Plasmodium falciparum. Malar. J.14, 490 (2015). PubMedPubMed Central Google Scholar
Wells, T. N., Burrows, J. N. & Baird, J. K. Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. Trends Parasitol.26, 145–151 (2010). PubMed Google Scholar